EGFR and cancer: We then exploited the GDSC database and found that in a variety of cancer cells, mutations in KRAS, NRAS, and BRAF were associated with resistance to common EGFR inhibitors like Gefitinib and Afatinib, in spite of some mutations that did not pass false discovery rate (FDR), possibly due to complexity of genetic background throughout so many cancer types (Fig. 1A–B; Suppl.